GlaxoSmithKline ROA 2006-2018 | GSK

Current and historical return on assets (ROA) values for GlaxoSmithKline (GSK) over the last 10 years.
GlaxoSmithKline Annual ROA - Return on Assets
2017 3.85
2016 1.80
2015 15.66
2014 10.31
2013 12.92
2012 13.35
2011 13.71
2010 15.27
2009 14.66
2008 13.47
2007 17.12
2006 21.52
2005 17.63
GlaxoSmithKline Quarterly ROA - Return on Assets
Q2 2018 0.82
Q1 2018 1.88
Q4 2017 -0.60
Q3 2017 2.37
Q2 2017 -0.15
Q1 2017 2.07
Q4 2016 0.60
Q3 2016 1.51
Q2 2016 -0.85
Q1 2016 0.65
Q4 2015 -0.66
Q3 2015 1.01
Q2 2015 0.28
Q1 2015 13.93
Q4 2014 2.32
Q3 2014 0.96
Q2 2014 1.70
Q1 2014 1.71
Q4 2013 5.96
Q3 2013 2.46
Q2 2013 2.49
Q1 2013 2.20
Q4 2012 2.08
Q3 2012 2.83
Q2 2012 2.95
Q1 2012 3.34
Q4 2011 2.99
Q3 2011 3.28
Q2 2011 2.62
Q1 2011 3.58
Q4 2010 -1.72
Q3 2010 3.15
Q2 2010 -0.67
Q1 2010 2.96
Q4 2009 4.06
Q3 2009 3.31
Q2 2009 4.06
Q1 2009 2.99
Q4 2008 2.05
Q3 2008 3.89
Q2 2008 4.05
Q1 2008 4.36
Q4 2007 3.54
Q3 2007 4.87
Q2 2007 5.05
Q1 2007 8.67
Q4 2006 4.90
Q3 2006 5.55
Q2 2006 5.09
Q1 2006 5.47
Q4 2005 4.08
Q3 2005 4.88
Q2 2005 4.84
Q1 2005 5.35
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $98.701B $38.892B
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $347.436B 16.60
Pfizer (PFE) United States $242.341B 14.19
Novartis AG (NVS) Switzerland $190.356B 16.33
Merck (MRK) United States $179.189B 15.82
AbbVie (ABBV) United States $145.249B 14.19
Novo Nordisk (NVO) Denmark $118.145B 18.89
Eli Lilly (LLY) United States $110.019B 20.37
Sanofi (SNY) France $103.584B 13.11
AstraZeneca (AZN) United Kingdom $98.732B 10.86
Bristol-Myers Squibb (BMY) United States $98.007B 17.74